The European Medicines Agency and the European Commission have had confidentiality arrangements with the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health and Ageing since 2012, to allow the exchange of information between the parties as part of their regulatory and scientific processes. The European Union (EU) and Australia also have a mutual recognition agreement (MRA) in place on good manufacturing practice (GMP) compliance.

Confidentiality arrangement

EMA, the European Commission and TGA signed a confidentiality arrangement in 2012.

The confidential information that EMA and TGA can share includes:

Exchange of letters

MRA and collaboration on GMP compliance

The EU and Australia have signed an MRA on GMP. This allows EU authorities and their Australian counterparts to:

  • rely on each other's GMP inspections of manufacturers in their respective territories;
  • waive batch testing of products on entry into their territories;
  • share information on inspections and quality defects.

For more information on MRAs and the scope of the EU-Australia MRA, see Mutual recognition agreements.

EMA also participates in initiatives with partner authorities, including the TGA, on GMP inspections which aim to better distribute inspections capacity, allowing more sites to be monitored and reducing unnecessary duplication. For more information, see International collaboration on GMP inspections.

Cluster activities

The agencies, together with other non-EU regulators, hold regular meetings by phone or videoconference in so-called 'clusters'.

The clusters are areas of cooperation focusing on special topics and therapeutic areas identified as requiring an intensified exchange of information and collaboration.

For more information, see Cluster activities with regulatory partners.

How useful was this page?

Add your rating
3 ratings